Literature DB >> 19570873

Viral persistence and chronic immunopathology in the adult central nervous system following Coxsackievirus infection during the neonatal period.

Ralph Feuer1, Chelsea M Ruller, Naili An, Jenna M Tabor-Godwin, Ross E Rhoades, Sonia Maciejewski, Robb R Pagarigan, Christopher T Cornell, Stephen J Crocker, William B Kiosses, Ngan Pham-Mitchell, Iain L Campbell, J Lindsay Whitton.   

Abstract

Coxsackieviruses are significant human pathogens, and the neonatal central nervous system (CNS) is a major target for infection. Despite the extreme susceptibility of newborn infants to coxsackievirus infection and viral tropism for the CNS, few studies have been aimed at determining the long-term consequences of infection on the developing CNS. We previously described a neonatal mouse model of coxsackievirus B3 (CVB3) infection and determined that proliferating stem cells in the CNS were preferentially targeted. Here, we describe later stages of infection, the ensuing inflammatory response, and subsequent lesions which remain in the adult CNS of surviving animals. High levels of type I interferons and chemokines (in particular MCP-5, IP10, and RANTES) were upregulated following infection and remained at high levels up to day 10 postinfection (p.i). Chronic inflammation and lesions were observed in the hippocampus and cortex of surviving mice for up to 9 months p.i. CVB3 RNA was detected in the CNS up to 3 months p.i at high abundance ( approximately 10(6) genomes/mouse brain), and viral genomic material remained detectable in culture after two rounds of in vitro passage. These data suggest that CVB3 may persist in the CNS as a low-level, noncytolytic infection, causing ongoing inflammatory lesions. Thus, the effects of a relatively common infection during the neonatal period may be long lasting, and the prognosis for newborn infants recovering from acute infection should be reexplored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570873      PMCID: PMC2738251          DOI: 10.1128/JVI.02382-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Quantitative analysis of viral RNA kinetics in coxsackievirus B3-induced murine myocarditis: biphasic pattern of clearance following acute infection, with persistence of residual viral RNA throughout and beyond the inflammatory phase of disease.

Authors:  K Nundita Reetoo; Shabina A Osman; Shirin J Illavia; Charlotte L Cameron-Wilson; Jangu E Banatvala; Peter Muir
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

3.  Inhibition of protein trafficking by coxsackievirus b3: multiple viral proteins target a single organelle.

Authors:  Christopher T Cornell; William B Kiosses; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro.

Authors:  V C Asensio; J Maier; R Milner; K Boztug; C Kincaid; M Moulard; C Phillipson; K Lindsley; T Krucker; H S Fox; I L Campbell
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication.

Authors:  R Wessely; K Klingel; K U Knowlton; R Kandolf
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

6.  Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis.

Authors:  A Pagenstecher; S Lassmann; M J Carson; C L Kincaid; A K Stalder; I L Campbell
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

7.  Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.

Authors:  M K Slifka; R Pagarigan; I Mena; R Feuer; J L Whitton
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

8.  Molecular mechanisms of coxsackievirus persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution.

Authors:  P E Tam; R P Messner
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  SJL and NOD macrophages are uniquely characterized by genetically programmed, elevated expression of the IL-12(p40) gene, suggesting a conserved pathway for the induction of organ-specific autoimmunity.

Authors:  D G Alleva; E B Johnson; J Wilson; D I Beller; P J Conlon
Journal:  J Leukoc Biol       Date:  2001-03       Impact factor: 4.962

10.  Poliovirus 3A protein limits interleukin-6 (IL-6), IL-8, and beta interferon secretion during viral infection.

Authors:  D A Dodd; T H Giddings; K Kirkegaard
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

View more
  40 in total

1.  Human astrocytic cells support persistent coxsackievirus B3 infection.

Authors:  Xiaowei Zhang; Zhenhua Zheng; Bo Shu; Xijuan Liu; Zhenfeng Zhang; Yan Liu; Bingke Bai; Qinxue Hu; Panyong Mao; Hanzhong Wang
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 2.  Virus infections as potential targets of preventive treatments for type 1 diabetes.

Authors:  Noora Nurminen; Sami Oikarinen; Heikki Hyöty
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Neural stem cell depletion and CNS developmental defects after enteroviral infection.

Authors:  Chelsea M Ruller; Jenna M Tabor-Godwin; Donn A Van Deren; Scott M Robinson; Sonia Maciejewski; Shea Gluhm; Paul E Gilbert; Naili An; Natalie A Gude; Mark A Sussman; J Lindsay Whitton; Ralph Feuer
Journal:  Am J Pathol       Date:  2011-12-31       Impact factor: 4.307

4.  A novel population of myeloid cells responding to coxsackievirus infection assists in the dissemination of virus within the neonatal CNS.

Authors:  Jenna M Tabor-Godwin; Chelsea M Ruller; Nolan Bagalso; Naili An; Robb R Pagarigan; Stephanie Harkins; Paul E Gilbert; William B Kiosses; Natalie A Gude; Christopher T Cornell; Kelly S Doran; Mark A Sussman; J Lindsay Whitton; Ralph Feuer
Journal:  J Neurosci       Date:  2010-06-23       Impact factor: 6.167

Review 5.  Enteroviruses in the pathogenesis of type 1 diabetes.

Authors:  Sisko Tauriainen; Sami Oikarinen; Maarit Oikarinen; Heikki Hyöty
Journal:  Semin Immunopathol       Date:  2010-04-28       Impact factor: 9.623

6.  Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis.

Authors:  Jason D Graci; Nina F Gnädig; Jessica E Galarraga; Christian Castro; Marco Vignuzzi; Craig E Cameron
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

7.  Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.

Authors:  Sheng Tang; Lanying Kong; Yinghong Li; Jiandong Jiang; Limei Gao; Xinyue Cheng; Linlin Ma; Xin Zhang; Yuhuan Li; Danqing Song
Journal:  ACS Med Chem Lett       Date:  2015-01-07       Impact factor: 4.345

8.  Immunohistochemical analysis of the relationship between islet cell proliferation and the production of the enteroviral capsid protein, VP1, in the islets of patients with recent-onset type 1 diabetes.

Authors:  A Willcox; S J Richardson; A J Bone; A K Foulis; N G Morgan
Journal:  Diabetologia       Date:  2011-05-20       Impact factor: 10.122

Review 9.  Treatment of perinatal viral infections to improve neurologic outcomes.

Authors:  William J Muller
Journal:  Pediatr Res       Date:  2016-09-27       Impact factor: 3.756

10.  Coxsackievirus B3 infects the bone marrow and diminishes the restorative capacity of erythroid and lymphoid progenitors.

Authors:  Nadine Althof; J Lindsay Whitton
Journal:  J Virol       Date:  2012-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.